EHRA Premium Access

Who should receive the Wearable Cardioverter Defibrillator (WCD)? Evidence and risk stratification for prevention of sudden cardiac death

Event: EHRA 2019
Topic: Prevention
Session type: Satellite Symposium
Sponsored by ZOLL
Date: 18 March 2019
Time: 12:45 - 13:45

Session

5 presentations in this session

Introduction - Who should receive the Wearable Cardioverter Defibrillator (WCD)? Evidence and risk stratification for prevention of sudden cardiac death.

Speaker: Doctor G. Botto (Garbagnate Milanese, IT)
Thumbnail

Distilling the clinical evidence behind the WCD - What have clinical trials and registries told us?

Speaker: Doctor S. Reif (Munich, DE)
Thumbnail

Strategies for screening and identifying which patients to protect with the WCD.

Speaker: Professor J. Ehrlich (Wiesbaden, DE)
Thumbnail

The impact of the WCD for patients who choose to wear it.

Speaker: Professor D. Scherr (Graz, AT)
Thumbnail

Panel discussion and summary - Who should receive the Wearable Cardioverter Defibrillator (WCD)? Evidence and risk stratification for prevention of sudden cardiac death.

Speaker: Doctor O. Piot (Saint Denis, FR)
Thumbnail

5 speakers from this session

Doctor Giovanni Luca Botto

ASST Rhodense, Garbagnate Milanese (Italy)
11 presentations
0 follower

Doctor Sebastian Reif

Munich Clinic Bogenhausen, Munich (Germany)
1 presentation
0 follower

Professor Joachim Ehrlich

St. Josefs-Hospital, Wiesbaden (Germany)
2 presentations
0 follower

Professor Daniel Scherr

Medical University of Graz, Graz (Austria)
12 presentations
0 follower

Doctor Olivier Piot

Centre Cardiologique du Nord, Saint Denis (France)
3 presentations
0 follower

This platform is supported by

logo Novo Nordisk